TruaceTracing the truth around AIMonday, August 17, 2026
Health·The Trace·Dual reading·Published 2026-08-06

English-to-Spanish translation equivalence of oncology clinical trial informed consent forms

Source article: Evaluating Artificial Intelligence Translation Tools for Language Equivalence of Oncology-Informed Consent Forms From English to Spanish

Abstract: Approximately 8% of the US population speaks primary languages other than English. Limited English proficiency (LEP) contributes to under-representation of Hispanic patients in oncology clinical trials. Although certified translation services exist, they are time-consuming and costly. Artificial intelligence (AI)-generated translations of informed consent forms (ICFs) could provide low-cost alternatives, but data on accuracy and safety remain limited. We evaluated language equivalence of English-to-Spanish trans…

TRV-2026-0663Peer-reviewedPermanent record — cite & verify
Trace impact reading

Negative state: both sides are scored from claims and sources, not community votes.

P 71The P score combines the specificity and measured human impact of the grounded problem claim with the strength of this Trace’s cited sources.G 62The G score combines the specificity and measured human impact of the grounded gain claim with the strength of this Trace’s cited sources.
Evaluating Artificial Intelligence Translation Tools for Language Equivalence of Oncology-Informed Consent Forms From English to Spanish

"Friends of Cancer Research" by MDGovpics is licensed under CC BY 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/2.0/.

The quick read

On August 5, 2026, a peer-reviewed study in JCO Oncology Practice evaluated AI translation of three oncology clinical trial informed consent forms from English to Spanish, comparing DeepL Pro, ChatGPT-4o, and a medically trained model Med_English2Spanish against certified translations using five equivalence domains scored by two bilingual physicians.

The findings matter because limited English proficiency contributes to under-representation of Hispanic patients in oncology trials, and low-cost AI could reduce barriers, but variable performance and safety concerns mean human review remains required and broader validation across more forms, languages, and raters is still needed.

Main points
  • Study compared DeepL Pro, ChatGPT-4o, and Med_English2Spanish against certified translations for three oncology ICFs.
  • Equivalence scored on five-point Likert scale across Semantic, Idiomatic, Experiential, Conceptual, and Safety domains by two bilingual physicians.
  • Certified translations highest at mean 4.99, ChatGPT-4o at 4.89, DeepL Pro at 4.43, Med_English2Spanish lowest at 3.32.
  • Authors concluded AI translations not suitable for clinical deployment without human review but warrant further study to reduce language barriers.
Gain

General-purpose AI tool ChatGPT-4o achieved near-certified translation equivalence for English-to-Spanish oncology informed consent forms.

Problem

Low-cost AI translations of oncology informed consent forms showed variable language equivalence and remain unsuitable for clinical use without human review.

The rundown

Researchers tested English-to-Spanish translation of three oncology trial ICFs using DeepL Pro, ChatGPT-4o, and Med_English2Spanish versus certified translations, scoring five domains on a five-point Likert scale.

Two bilingual board-certified physicians scored independently with high inter-rater agreement (weighted kappa 0.95), finding certified translations at 4.99 mean, ChatGPT-4o at 4.89, DeepL Pro at 4.43, and Med_English2Spanish at 3.32.

What this doesn’t fix

Exploratory evaluation limited to three oncology ICFs and two physician raters, with variable equivalence across tools and domains.

Sources

Reader signal

How should this claim be treated?

The debate